A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors

ClinicalTrials.gov ID: NCT06619587

Public ClinicalTrials.gov record NCT06619587. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 5, 2026, 6:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I/II Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors With a KRAS G12D Mutation

Study identification

NCT ID: NCT06619587
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Genentech, Inc.; Industry
Enrollment: 410 participants

Conditions and interventions

Conditions

Solid Tumor

Interventions

Phase I Arm A Drug
Phase I Arm B Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 13, 2024
Primary completion: May 30, 2028
Completion: May 30, 2028
Last update posted: May 3, 2026

2024 – 2028

United States locations

U.S. sites: 12
U.S. states: 11
U.S. cities: 12

Facility	City	State	ZIP	Site status
UC San Diego Moores Cancer Center	La Jolla	California	92093-1503	Recruiting
Sarah Cannon Research Institute at HealthONE	Denver	Colorado	80218	Recruiting
Yale Cancer Center	New Haven	Connecticut	06510	Recruiting
Florida Cancer Specialist-Lake Mary	Lake Mary	Florida	32746	Completed
University of Illinois	Chicago	Illinois	60612	Recruiting
Dana Farber Cancer Institute	Boston	Massachusetts	02215	Recruiting
START - Midwest - EDOS	Grand Rapids	Michigan	49546-7062	Recruiting
Montefiore Einstein Cancer Center	The Bronx	New York	10461	Recruiting
Mary Crowley Medical Research Center	Dallas	Pennsylvania	75230-2571	Recruiting
Abramson Cancer Center;Univ of Pennsylvania	Philadelphia	Pennsylvania	19104-5127	Recruiting
SCRI Oncology Partners	Nashville	Tennessee	37203	Recruiting
O'Quinn Medical Tower at McNair Campus	Houston	Texas	77054	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06619587, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 3, 2026 · Synced May 5, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06619587 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →